View Older Stories View More Recent Stories
-
INVESTOR ALERT: Class Action Lawsuit Against Iconix Brand Group, Inc. Filed by Glancy Prongay & Murray LLP
-
Streetinsider.com's Hot Lunchtime Reads 6/23: (GOOG) (WMT) (UAL) (DMRC)
-
Roth Capital Downgrades Vical (VICL) to Neutral
-
Roth Capital Raised Price Target on Escalade (ESCA) Following Investor Meetings
-
Sequential Brands (SQBG) Announces Acquisition of Martha Stewart Living Omnimedia (MSO); Roth Capital Raises Price Target to $20
-
Magellan Petroleum (MPET) Flagship Results Better Than Expected; Roth Capital Raises Price Target to $2
-
Quest Resource Holding Corporation to Participate in ROTH Cleantech Investor Day in London on June 25, 2015
-
Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'
-
Orbite to Participate in a Cleantech Investor Event in London, U.K.
-
Roth Capital Starts NTN Buzztime (NTN) at Neutral
-
Ameresco to Present at ROTH London Cleantech Day
-
Roth Capital Sees SodaStream (SODA) Results Lackluster Short Term But Rebounding in Q4; PT to $29
-
TG Therapeutics (TGTX) Data Acts as Strong GENUINE Proxy, Roth Capital Says
-
Ring Energy (REI) Prices 4.5M Common Stock Offering at $11.50/Share
-
Ring Energy, Inc. Announces Pricing of Public Offering of Common Stock
-
Competitor IPO Filing Shows Callidus Software's (CALD) Srength; Roth Capital reiterates Buy
-
Roth Capital Remains Bullish on Align Technology (ALGN) After ClearCorrect's Patent Reexamination Request was Granted
-
Roth Capital Cuts PT on Capstone Turbine (CPST) to 50c; Challenging End Markets Hamper Q4 Results
-
Eco-stim Energy Solutions (ESES) Announces $30M Common Offering
-
Eco-Stim Energy Solutions Announces Public Offering of Shares of Common Stock
-
Eco-Stim Energy Solutions Announces Public Offering of Shares of Common Stock
-
ROTH Capital Partners to Host Cleantech Day in London on June 25, 2015
-
Roth Capital Downgrades Insite Vision (INSV) to Neutral
-
BioCardia (BCDA) Files $57.5M Common Stock IPO
-
Spark Therapeutics to Participate in Two International Conferences in London in June
-
Spark Therapeutics to Participate in Two International Conferences in London in June
-
Roth Capital Starts Quest Resource (QRHC) at Buy
-
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering
-
ROTH Capital Partners to Host Healthcare Day In London on June 24, 2015
-
Roth Capital Remains Bullish Following Motorcar Parts of America (MPAA) FQ4 Beat
-
Roth Capital Starts Trevena (TRVN) at Buy, $14.50 PT
-
Roth Capital Raises Price Target on Iradimed Corp. (IRMD) After traveling with Management
-
Pace of ECCO-50 Development in OA Patients Remains Robust; Roth Affirms Cytori Therapeutics (CYTX) at 'Buy'
-
Redhill Biopharma (RDHL) PT Raised to $30 at Roth Capital
-
Bio Blast Pharma (ORPN) PT Raised to $25 at Roth Capital
-
Galena Biopharma's (GALE) GALE-401 Phase 2 Shows Potential Advantage of IR formulation; Roth Affirms at 'Buy'
-
Consolidated Water Co. Ltd. to Participate in ROTH Capital Partners "Cleantech Day" on June 25, 2015 in London
-
Roth Capital Raises Price Target on Sunesis Pharmaceuticals (SNSS) Following EHA Presentation
-
bluebird bio (BLUE) Bullish Stance Reiterated at Roth Capital Following HGB-205 Study Data
-
Challenged Athletes Foundation Raises More Than $2 Million at Ninth Annual Gala in New York City
-
Notable 52-Week Highs and Lows 6/12: (FOLD) (KFY) (AGEN) High; (GMCR) (LF) (ZQL) Low
-
Positive Trend for MEI Pharma's (MEIP) Pracinostat in Frontline AML Continues; Roth Affirms at 'Neutral'
-
Promacta Receives FDA Approval for Children with ITP; Roth Raffirms Ligan Pharma (LGND) at 'Buy' (NVS)
-
Roth Capital Cuts Price Target on LeapFrog Enterprises (LF) Following EPS Miss
-
ContraFect Corporation Announces $20,000,000 Private Placement
-
Notable 52-Week Highs and Lows 6/11: (C) (LLY) (MW) High; (CHK) (ZQK) (MARA) Low
-
Biotie Therapies (BITI) IPO Opens Up 22%
-
Pre-Open Stock Movers 06/11: (ASTI) (BOX) (KKD) Higher; (GLP) (DRNA) (TUBE) Lower (more...)
-
Roth Capital Remains Bullish on Krispy Kreme Doughnuts (KKD) Following 1Q16
-
Roth Capital Starts PlasmaTech Bio (PTBI) at Buy, $16 PT

